Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

DBP receives EU funding SME instrument Phase I

Read the release

"I am glad that we continue receiving support from the European Commission for our projects," comments CEO Igor Lokot. - It is tough competition for Horizon2020 funds in general and for the SME Instrument program In particular, and we see the positive decision as an important quality stamp for our actions and our ambitions".

More about SMEi phase I: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/sme-instrument

More about SI-053: SI-053 is an innovative drug that is being developed by DBP for the treatment of operable brain cancers, in particular the most aggressive type glioblastoma. SI-053 is today at the edge of entering of the clinical phase of its development and the pre-clinical phase is expected to be completed within a few months. SI-053 has Orphan Drug Designation from EMA since 2016 and the international patent application to protect the technology has resulted so far in an approved patent for SI-053 in Eurasia.

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8 of April 2019.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.